Online citations, reference lists, and bibliographies.
← Back to Search

Repeated Observation Of Breast Tumor Subtypes In Independent Gene Expression Data Sets

T. Sørlie, R. Tibshirani, Joel Parker, T. Hastie, J. Marron, A. Nobel, S. Deng, H. Johnsen, R. Pesich, S. Geisler, J. Demeter, C. Perou, P. Lønning, P. Brown, Anne-Lise Børresen-Dale, D. Botstein
Published 2003 · Medicine, Biology

Cite This
Download PDF
Analyze on Scholarcy
Share
Characteristic patterns of gene expression measured by DNA microarrays have been used to classify tumors into clinically relevant subgroups. In this study, we have refined the previously defined subtypes of breast tumors that could be distinguished by their distinct patterns of gene expression. A total of 115 malignant breast tumors were analyzed by hierarchical clustering based on patterns of expression of 534 “intrinsic” genes and shown to subdivide into one basal-like, one ERBB2-overexpressing, two luminal-like, and one normal breast tissue-like subgroup. The genes used for classification were selected based on their similar expression levels between pairs of consecutive samples taken from the same tumor separated by 15 weeks of neoadjuvant treatment. Similar cluster analyses of two published, independent data sets representing different patient cohorts from different laboratories, uncovered some of the same breast cancer subtypes. In the one data set that included information on time to development of distant metastasis, subtypes were associated with significant differences in this clinical feature. By including a group of tumors from BRCA1 carriers in the analysis, we found that this genotype predisposes to the basal tumor subtype. Our results strongly support the idea that many of these breast tumor subtypes represent biologically distinct disease entities.
This paper references
10.1038/415436a
Prediction of central nervous system embryonal tumour outcome based on gene expression
Scott L. Pomeroy (2002)
10.1016/S0002-9440(10)64476-8
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome.
M. van de Rijn (2002)
10.1056/NEJM200102223440801
Gene-expression profiles in hereditary breast cancer.
I. Hedenfalk (2001)
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns.
S. Gruvberger (2001)
Nat. Med
D G Beer (2002)
10.1056/NEJMOA012914
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
A. Rosenwald (2002)
Cancer Res
S Geisler (2001)
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
S. Geisler (2001)
10.1001/JAMA.1979.03290310029009
On the diagnosis and treatment of breast cancer.
M. S. Fox (1979)
Proc. Natl. Acad. Sci. USA 98
M E Garber (2001)
10.1073/pnas.191367098
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T. Sørlie (2001)
10.1016/S0140-6736(02)11087-7
BRCA1: mechanisms of inactivation and implications for management of patients
R. Kennedy (2002)
10.1073/pnas.201162998
Predicting the clinical status of human breast cancer by using gene expression profiles
M. West (2001)
Cancer Res
T A Grushko (2002)
Cancer Res
D A Wigle (2002)
10.1073/pnas.241500798
Diversity of gene expression in adenocarcinoma of the lung
M. E. Garber (2001)
Nat. Med
M A Shipp (2002)
10.1038/nm0102-68
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
M. Shipp (2002)
Proc. Natl. Acad. Sci. USA 98
T Sørlie (2001)
Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.
J. Armes (1999)
N. Engl. J. Med
A Rosenwald (2002)
10.1007/s00439-002-0804-5
Associations between gene expressions in breast cancer and patient survival
T.-K. Jenssen (2002)
10.1056/NEJMOA021967
A gene-expression signature as a predictor of survival in breast cancer.
M. J. van de Vijver (2002)
Cancer Res
S Gruvberger (2001)
10.1093/nar/gkg014
SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data
M. Diehn (2003)
Hum. Genet
T K Jenssen (2002)
N. Engl. J. Med
Van De Vijver (1999)
10.1038/35021093
Molecular portraits of human breast tumours
C. Perou (2000)
10.1091/MBC.02-02-0023
Gene expression patterns in human liver cancers.
X. Chen (2002)
J. Am. Med. Assoc
M S Fox (1979)
Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
T. Grushko (2002)
Nucleic Acids Res
M Diehn (2003)
10.1038/35000501
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh (2000)
10.1038/nm733
Gene-expression profiles predict survival of patients with lung adenocarcinoma
D. Beer (2002)
Cancer Res
J E Armes (1999)
Mol. Biol. Cell
X Chen (2002)
10.1172/JCI15795
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer.
S. Signoretti (2002)
Molecular profiling of non-small cell lung cancer and correlation with disease-free survival.
D. Wigle (2002)
Proc. Natl. Acad. Sci. USA 98
M West (2001)
10.1073/pnas.082099299
Diagnosis of multiple cancer types by shrunken centroids of gene expression
R. Tibshirani (2002)
10.1016/S0140-6736(02)08270-3
Molecular characterisation of soft tissue tumours: a gene expression study
T. Nielsen (2002)
Clin. Cancer Res
S Geisler (2003)
N. Engl. J. Med
I Hedenfalk (2001)
J. Clin. Invest. Am. J. Pathol
S Signoretti (1991)
Proc. Natl. Acad. Sci. USA 99
R Tibshirani (2002)
10.1038/415530a
Gene expression profiling predicts clinical outcome of breast cancer
L. J. Veer (2002)



This paper is referenced by
10.1186/bcr2486
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins
Hideki Asakawa (2009)
10.1002/cncr.22890
Effects of supportive‐expressive group therapy on survival of patients with metastatic breast cancer
D. Spiegel (2007)
10.1016/J.EJCA.2004.07.024
Gene expression microarray technologies in the development of new therapeutic agents.
P. Clarke (2004)
10.3816/CBC.2005.N.010
Bringing molecular prognosis and prediction to the clinic.
M. Colozza (2005)
10.1016/j.jsbmb.2005.04.028
Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer
V. Kristensen (2005)
10.2217/14796694.1.4.485
Clinical application of molecular profiling in breast cancer.
J. Sparano (2005)
Die Bedeutung des quantitativen immunhistochemischen Nachweises von Protein S100A6 beim Mammakarzinom
A. Gerteis (2006)
"Basal-like" Breast Carcinomas: Identification by P-cadherin, P63 and EGFR Basal Cytokeratins Expression
J. Paredes (2006)
10.1007/978-3-540-31748-7_16
Genetische Veränderungen des sporadischen Mammakarzinoms
N. Arnold (2006)
10.1016/J.EJCA.2005.11.021
High-throughput techniques in breast cancer: a clinical perspective.
E. Espinosa (2006)
10.1200/JCO.2005.04.6524
Molecular forecasting of breast cancer: time to move forward with clinical testing.
Sherene Loi (2006)
10.1007/s00432-006-0108-6
A clinical prognostic prediction of lymph node-negative breast cancer by gene expression profiles
D. Jiang (2006)
10.1086/504090
Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation.
F. Weber (2006)
10.1051/MEDSCI/20072367626
Les cancers du sein - Vers un modèle cellulaire et moléculaire intégré
E. Charafe-Jauffret (2007)
10.1038/ncpuro0946
Mechanisms of Disease: biomarkers and molecular targets from microarray gene expression studies in prostate cancer
C. Cooper (2007)
10.1016/j.mce.2004.02.021
About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-α gene (ESR1) in breast cancer
M. Lacroix (2004)
10.1634/THEONCOLOGIST.9-SUPPL_3-20
Overcoming endocrine therapy resistance by signal transduction inhibition.
M. Ellis (2004)
Perinucleolar compartment prevalence has an independent prognostic value for breast cancer.
R. V. Kamath (2005)
10.1016/j.humpath.2007.07.014
The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
O. Fadare (2008)
10.2217/14796694.4.2.271
Clinical proteomics and breast cancer: strategies for diagnostic and therapeutic biomarker discovery.
F. Bertucci (2008)
10.1700/363.4228
Factors predictive of response to hormone therapy in breast cancer.
F. Rastelli (2008)
10.1159/000164270
The Ethnic Profile of Triple-Negative Breast Cancer
S. Cleator (2008)
Molecular analysis of early onset Indonesian breast cancer
D. Purnomosari (2006)
10.1155/2007/281727
Matrix Metalloproteinase Expression Patterns in Luminal A Type Breast Carcinomas
J. Decock (2007)
10.1093/ANNONC/MDM522
MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer.
Y. Eralp (2008)
10.1016/J.CANLET.2006.03.031
Integrin signaling in epithelial cells.
M. Gilcrease (2007)
10.1007/s00129-007-1983-x
Molekulares Staging und Vorhersage von Therapieansprechen beim Mammakarzinom
G. Sauer (2007)
10.1016/J.BREAST.2007.02.006
The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial.
A. Rody (2007)
10.1016/J.CLINTHERA.2007.08.013
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
M. Jahanzeb (2007)
10.1007/978-1-60327-553-8_23
Transcription Profiling of Brain Tumors: Tumor Biology and Treatment Stratification
E. Sulman (2009)
RESEARCH REVIEW GATA-3 as a Marker of Hormone Response in Breast Cancer
Sandy H. Fang (2009)
10.1186/1471-2105-10-S1-S19
A voting approach to identify a small number of highly predictive genes using multiple classifiers
M. R. Hassan (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar